Assyro AI
Orange Book product · Brand (NDA)

Actifed W/ Codeine

Codeine Phosphate; Pseudoephedrine Hydrochloride; Triprolidine Hydrochloride

Brand (NDA)NDA 012575Discontinued Glaxosmithkline
Approved
Apr 04, 1984
Application
Brand (NDA)
TE code
Not listed
Listed patents
0
Actifed W/ Codeine (Codeine Phosphate; Pseudoephedrine Hydrochloride; Triprolidine Hydrochloride) is Glaxosmithkline's brand-name drug, approved by the FDA under NDA 012575 in 1984. Its marketing status is listed as discontinued; a discontinued listing is not, by itself, a finding that the drug was withdrawn for safety or effectiveness. 3 approved generics share this drug's active ingredient.

Sourced from the FDA Orange Book

Approval, patents, exclusivity

Key dates

Key dates

  1. Approval

    FDA approval date of this drug product.

    Apr 04, 1984

    42 yr 11 mo ago

  2. Today

FDA product record

Pharmaceutical detail

Pharmaceutical detail

Active ingredient

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

Strength

10MG/5ML;30MG/5ML;1.25MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Dosage form

SYRUP

Route

ORAL

TE code

Not listed

Application

NDA 012575

Product number

003

Marketing status

Discontinued

Reference listed drug (RLD)

No

Reference standard (RS)

No

Brand + generics

Active-ingredient family

Orange Book patent file

Listed patents

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Actifed W/ Codeine — frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this product, from the FDA Orange Book.

Built directly from the FDA Orange Book data file. This product page links back to the Codeine Phosphate; Pseudoephedrine Hydrochloride; Triprolidine Hydrochloride active-ingredient family, which is the canonical reference for generics, patents, and exclusivity across all strengths.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.